By - Sreenivas D Ajankar
Highlights
- Over the years, investors’ interest in the AIM-listed stocks has increased mainly due to many innovative growth-orientated companies listed on the segment.
- The FTSE AIM All-Share index 5-year total return was 52.8% as of 31 December 2021.
The Alternative Investment Market (AIM), a submarket and a specialised unit of the London Stock Exchange, provides a platform for smaller companies and startups to increase their reach and raise capital from the public market. Over the years, investors’ interest in the AIM-listed stocks has increased mainly due to innovative and growth-orientated companies listed on the segment.
In the long run, the index has given good returns to investors. The FTSE AIM All-Share index 3-year total return was 46.3%, while its 5-year total return was 52.8% as of 31 December 2021.
© 2022 Kalkine Media®
Let us look at 3 AIM-listed stocks that are in focus today for some or other reasons:
The company operates in the pharmaceutical segment and is engaged in commercial medicines and clinical trial services to its clients. The firm has received a revised takeover bid by the UK-based private equity firm, Triton Funds.
The new upgraded all-cash offer is to acquire the entire issued and to be issued shares of the company at a price of 925p per share, valuing the firm at £1.3 billion. The company’s board has agreed to an increased final offer and has recommended it to its shareholders as well. The new offer represent an increase of 42p compared to the previous takeover bid of 883p per share made in December 2021.
Clinigen Group Plc currently trades at GBX 896, down by 0.99% on 17 January 2022 at 10:30 am GMT+1, with a market cap of £1,206 million.
The upstream oil and gas company is engaged in the development of different projects globally. Its main oil and gas properties are located in Romania and Tunisia.
The company reported significant business growth and turned profitable in the nine months to 30 September 2021. Its total revenue from operation was at USD 25.7 million, while its gross profit was USD 4.4 million (30 September 2020- Gross Loss: USD 1.7 million). The higher business growth was mainly due to a steady recovery in global crude oil and natural gas prices throughout the year.
Serinus Energy Plc currently trades at GBX 1.85, up by 13.85% on 17 January 2022 at 10:30 am GMT+1, with a market cap of £18.28 million.
The diagnostic platform company provides its client with a patented platform to test and detect infectious diseases. In December 2021, the share price was up by nearly 14.5% after the company announced that it had filed an approval application in the United Kingdom for its COV19-ID kit. Upon regulatory approval, the company can sell its diagnostic test kit in the UK. The test kit uses the RT-LAMP technology and delivers results in a short span of time. Also, the kit meets the UK testing standards and can detect all the variants of coronavirus.
Genedrive Plc currently trades at GBX 24.50, down by 6.67% on 17 January 2022 at 10:30 am GMT+1, with a market cap of £24.22 million.